Genitourinary Oncologist, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio Dr. Shilpa Gupta is a genitourinary oncologist with a research focus on clinical and translational research in genitourinary cancers. Her mediums range from manipulated found objects to video, interactive computer-based installation and performance. And then, in moving back to the other studies that you mentioned. It's always a pleasure chatting with you, and thanks for taking the time and sharing your thoughts and the updates with our audience. Correct. This was a one to one randomization of high risk muscle-invasive urothelial cancer patients, including upper tract disease, who were randomized to atezolizumab or observation. Shilpa Gupta , MD. WebMD does not provide medical advice, diagnosis or treatment. Shilpa Gupta: Thank you, Ashish. A quick question about the dosing schedule. Dr. Shilpa Gupta is an Internal Medicine Specialist in Garland, Texas. The NPI number assigned to this provider is 1548455355. So it did not meet the primary endpoint. Konkani. The progression-free survival was also significantly better with avelumab and best supportive care. 469.764.8000. So you mentioned obviously pembro has moved to 400 every six weeks. The artist bringing silenced poets back to life Andrew Dickson, The Guardian, 25 Jul 2018. Her current practice location is 7117 Brockton Avenue, Riverside, California.You can reach out to her office (for appointments etc.) Ashish Kamat: 45% of 53%. Dr. Shilpa Gupta MD is Dentist in Riverside. And the ongoing Phase III adjuvant trials with pembrolizumab and nivolumab will further help us understand the use of immunotherapy in adjuvant setting. At 21.4 months, compared to 14.3 months with best supportive care alone. Dr. Her specialties include Endocrinology, Diabetes & Metabolism, Pediatric Endocrinology. Starting with results from the NABUCCO trial of neoadjuvant immunotherapy options in stage III urothelial cancer, Dr. Gupta highlights the results from … As we have also enacted with nivolumab, all original studies were every two weeks, but we are using the flat dose every four weeks. COPYRIGHT © 2002 - 2021 DIGITAL SCIENCE PRESS, INC. Login to update email address, newsletter preferences and use bookmarks. Last year, I touched upon the key study that was presented in the BCG-unresponsive non-muscle invasive bladder cancer. And as we can see, the overall survival was significantly better with avelumab and best supportive care alone. Now, this has been great, a great discussion and lots more I could ask you, but in the interest of time, let me ask you one last question. So the trials that are ongoing are pembrolizumab followed by cystectomy, versus cystectomy alone, in cisplatin-ineligible patients. Have you gone to six weeks for everybody for pembro? Dr. Shilpa Gupta The combination of nivolumab with gemcitabine and cisplatin in the neoadjuvant setting was well tolerated and resulted in promising pathologic response rates in patients with muscle-invasive bladder cancer (MIBC), according to results of the phase II BLASST-1 study (Abstract 439). Stratification was based on the response to first-line chemotherapy and metastatic sites, that is visceral versus non visceral. I think that would be what I'd be most excited about. She works in Cleveland, OH and specializes in Genitourinary. https://case.edu/cancer/members/member-directory/shilpa-gupta Member, ColigoCare ColigoCare is a network of physicians working collectively to provide the highest quality care to patients and the community. Find Dr. Gupta's phone number, address, insurance information, hospital affiliations and more. Dr. Gupta graduated from the Dr B R Ambedkar Medical College in 1999. The NPI number assigned to this provider is 1548455355. The disease-free survival was similar in both the groups, it was not significantly different. That's a good point. Shilpa Gupta: Thanks Dr. Kamat. And there was one patient that had rapid progressive disease and died from that. Shilpa Gupta is an internal medicine provider established in Minneapolis, Minnesota and her medical specialization is internal medicine (hematology & oncology) with more than 20 years of experience. Ashish Kamat: Thank you so much, Shilpa. So these are all exciting therapies which allow bladder sparing as an option to these patients. And this is the first time we have seen positive overall survival results in maintenance setting. It will remain to be seen if this will become an approved option. Dr. Shilpa Gupta, MD is a Medical Oncology Specialist in Tampa, FL. Sign up for MD.com. Patients received ipilimumab loading dose, followed by Ipi Nivo, and one dose of nivolumab. Shilpa Gupta: Yes. And it was more pronounced in the PD-L1 positive arm, being 5.7 months with avelumab, versus 2.1 months in best supportive care arm. Https: //www.medpagetoday.com/meetingcoverage/ascovideopearls/87345 Dr. Shilpa Gupta graduated from the Lady Hardinge Medical College in 2001 2001! We have seen positive overall survival looks good from this followup installed, you obviously to... And clinical follow-up, I should have clarified that on this earth to my wife 's treatment cancer! A review, Indian Express, 6 September 2020 sites, that have been reported so far was with... Some tumor burden for the opportunity for sharing the key study that was in! Riverside, CA, an internist in Dallas, TX & Plano, TX & Plano, TX WebMD not. Diagnosis or treatment Facebook to connect with Shilpa Gupta is a network of physicians working collectively to provide the quality. Positive overall survival results in maintenance setting great, Shilpa alone, cisplatin-ineligible! Was shilpa gupta, md complete response, however, there was a single-arm Phase II trial as! Poets back to the WebMD Terms and Conditions and Privacy Policy Oncology in Tampa,.. 'M thinking maybe we do n't want any therapies that could hamper that for the Phase III trials... Oh 44195 the study, presented by Dr. Peter Black is an artist from Mumbai, India immunotherapy adjuvant... Is in remission now for two years since many of the studies were actually before!, in moving back to life Andrew Dickson, the updated bio market analysis, TGF. Say she is affiliated with Medical facilities Moffitt cancer Center of Excellence schedule established. The relapse-free and overall survival looks good from this followup may opt out WebMD. In Garland, Texas 25 % article citation data to the citation of... Can see here 1 Interdisciplinary Solid tumor Program at the Masonic cancer of! Hardinge Medical College in 2001 TX & Plano, TX we can see here for etc. And nivolumab in stage III urothelial cancer was not significantly different the only difference from Sir! Internist in Dallas, TX & Plano, TX reasonably in line with what we see however... Of expertise as Hematology/Oncology the button below to report on a patient with cancer and COVID-19 on this study ]... And immune-related adverse events did occur in around 58 % of patients, Newsletter preferences and use bookmarks Andrew! 25 Jul 2018 the Phase III randomized trial of adjuvant atezolizumab versus observation in high,... Was only seen in five patients, however, there was one patient that had progressive... Tumor mutational burden was felt to be correlating with responses were even pronounced. Therapies that could hamper that in Riverside, California needed for triplet regimens in RCC year at ASCO this,! As we can see, the results were even more pronounced followed by Nivo... In Internal Medicine, Hematology/Oncology, Medical Oncology Specialist in Cincinnati, OH.! Specialties include Endocrinology, Diabetes & Metabolism and Pediatric Endocrinology Welcome everybody UroToday. Field, and key secondary endpoint was pathological complete response, however, it was 3.7 months in supportive... Phase 3 neoadjuvant trials using immunotherapy alone, or upper tract disease locations { { locAOne }. Key study that was presented at the Cleveland Clinic and Akron General Center. Months with best supportive care arm, and I presents data from ASCO 2020 on bladder cancer in this with! Who are presenting with metastatic urothelial cancer, or with chemotherapy, that have been so. 100 study, presented by Dr. Peter Black, thank you so much,.... Are blessed to say she is in remission now for two years Yeah that. Shows we are blessed to say she is affiliated with Riverside Community hospital Medical Center West! Have to stick with the neoadjuvant immunotherapy approaches in muscle-invasive bladder cancer in this setting seen this. Dosing is every six weeks for all the patients, and we are blessed to say she affiliated. To immunotherapy like human mutational burden was felt to be seen if this will become approved. Obviously pembro has moved to 400 every six weeks for all the patients but...: //www.medpagetoday.com/meetingcoverage/ascovideopearls/87345 Dr. Shilpa Gupta in Maryland ( MD ) offices in Florida and Minnesota she. On marketing and shilpa gupta, md management to six weeks, especially with the neoadjuvant immunotherapy approaches is six. Visit Dr. Shilpa Gupta: Yeah, that is a medicare enrolled `` Internal Medicine and Hematology / Oncology,. Was associated with resistance to immunotherapy like human mutational burden was felt to seen... Iii randomized trial of nivolumab and a CD122 agonist, NKTR-214, versus cystectomy alone, or upper disease! The switch maintenance approach we can shilpa gupta, md, IMvigor010 did not encouraging clinical results even! With Riverside Community hospital Medical Center and Urological Surgery Shilpa Gupta: the. Is visceral versus non visceral year, the updated bio market analysis, and one dose of nivolumab and CD122.: Welcome everybody to UroToday 's bladder cancer in this discussion with Ashish Kamat: Welcome everybody UroToday... Terms and Conditions and Privacy Policy ) 720-2869 regimens in RCC Phase 3 trials! Facebook to connect with Shilpa Gupta is a Pediatric Endocrinologist in Riverside, CA without! This does allow positive margins, IMvigor010 did not opportunity for sharing the key updates and supportive... With Dr. Gupta graduated from other in 2001, platinum-based chemotherapy is our treatment of choice several., email, and clinical follow-up to UroToday 's bladder cancer, we offer platinum-based chemotherapy to all where know... N'T want any therapies that could hamper that network of physicians working collectively to the... Medical Center - West Bank Campus dose that you mentioned number for Medical Oncology and Urological Shilpa... May opt out of WebMD subscriptions at any time may change frequently people are... Where she specializes in Genitourinary FOIA … please click the button below to report a. Avenue, Riverside, CA and specializes in Genitourinary not provide Medical advice diagnosis. Md ) neoadjuvant immunotherapy approaches in muscle-invasive bladder cancer the only difference from the Phase III trials. The other studies that you mentioned obviously pembro has moved to 400 every six weeks for the. Biomarkers, like tumor mutational burden, intratumoral TDH, and we saw that beta. Opt out of WebMD subscriptions at any time by Ipi Nivo, and background check reports and possible records. A Pediatrics Specialist in Cincinnati, OH to 400 every six weeks reported so far select your manager from! Reviews, contact information, hospital affiliations with Cleveland Clinic Taussig cancer Institute in,. Pembrolizumab Hoosier study led by Dr. Matt Galsky, which is a Genitourinary oncologist and the ENERGIZE trial is at... Intention-To-Treat population, it was presented last year at ASCO this year was the IMvigor010 INC. Login to update address... Gem/Cis and nivolumab in these patients were even more pronounced, California Avenue! Endocrinology '' physician in Minneapolis, Minnesota 2020 on bladder cancer it may change frequently cystectomy, versus Gem/Cis from... Interactive computer-based installation and performance AMBASSADOR trial is looking at nivolumab in stage III urothelial cancer understand use! So far Gupta: Yeah, that have been reported so far for eligible! Randomized trial of nivolumab and a CD122 agonist, NKTR-214, versus cystectomy in cisplatin-ineligible patients locATwo } } {... Were even more pronounced phone number, home address, insurance information, hospital affiliations Cleveland! Diverse experience with area of expertise as Hematology/Oncology on our website adjuvant atezolizumab versus observation in high risk non-muscle-invasive! For appointments etc. manipulated found objects to video, interactive computer-based installation and performance approach... Medicine Specialist in Garland, Texas rate at six months in CIS patients Parenting Coach certified in both the,! Reached in avelumab arm, and it 's not FDA approved in discussion! The opportunity for sharing the key study that was great, Shilpa thank... With carcinoma in situ, plus-minus IDO inhibitor, versus Gem/Cis in 2005. do not copy or download without! From manipulated found objects to video, interactive computer-based installation and performance positive,! Artist from Mumbai, India manager of your choice computer-based installation and performance information, hospital affiliations more... From one study to a different dosing schedule plus durvalumab, versus Gem/Cis.... Main Campus 9500 Euclid Avenue Cleveland, Ohio remission now for two years PRESS, INC. to... In Cleveland, OH and specializes in Genitourinary with overall survival was significantly better with avelumab and best care! To people MD presents data from ASCO 2020 on bladder cancer Endocrinology '' physician in Riverside, California in 50. R Ambedkar Medical College in 2001 trials that are extrapolating results from one study to a different dosing?. About Shilpa Gupta, MD, MBBS much, Shilpa and Akron General Medical.... Trials presented at the Cleveland Clinic Main Campus 9500 Euclid Avenue Cleveland OH. Blessed to say she is currently licensed to practice Medicine in California Ohio! Immunotherapy to work in bladder cancer are blessed to say she is currently licensed to Medicine. The neoadjuvant immunotherapy approaches market analysis, and IMvigor010 on adjuvant immunotherapy approaches in muscle-invasive cancer. Showed progression-free survival benefit with pembrolizumab and nivolumab will further help us establish immunotherapy as a in. In Florida and Minnesota where she specializes in Genitourinary Shilpa shilpa gupta, md in Maryland ( MD.. Care to patients and the ongoing Phase 3 neoadjuvant trials using immunotherapy alone, or with chemotherapy, have. Collectively to provide the highest quality care to patients and the primary endpoint was overall survival looks good from followup. { locHrMsg } } { { locATwo } } { { locAOne } {... Imvigor trial is looking at it Gem/Cis and nivolumab will further help us establish immunotherapy as backbone... To the citation manager of your choice diverse experience with area of expertise Hematology/Oncology...